ArticleHemaSphere2025

Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry.

Jean Galtier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.